<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/95VC-ZP26" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method GTA-14: Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay</p><p><b>Protocol Abbreviation:</b> GTA-14</p><p><b>Protocol Version:</b> 1.2<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/95VC-ZP26>http://dx.doi.org/10.17917/95VC-ZP26</a></p><p><b>Protocol File:</b> protocols/20240410_18-45-43-167_NCL_Method_GTA-14.pdf<p><b>File Title:</b> GTA-14</p><p><b>Description:</b></b> This protocol describes the monitoring of nanoparticle treated human hepatocarcinoma cells (HepG2) for apoptosis, as part of the in vitro NCL preclinical characterization cascade.  The protocol utilizes a fluorescent method to measure Caspase-3/7 activation.  This is a homogeneous assay that does not require cell isolation, as required for HepG2 Hepatocarcinoma Apoptosis Assay (NCL Method GTA-6).<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>